Responsive Approaches: Adapting Our Work to the New Realities of COVID-19

As FHI Clinical begins supporting rapid start-up of clinical trials vital to containing the spread of COVID-19 and protecting the global community, we are also adapting our ongoing work to the new reality of this global pandemic. We are closely monitoring the situation on the ground in the countries where we work and repurposing team members to support COVID-19 response needs.

Many of our clinical research associates (CRAs) who conduct remote monitoring activities in Africa and Asia are now supporting our 24/7 call center for COVID-19 clinical trial center triaging. They are also answering protocol questions from sites worldwide so that we can quickly and efficiently enroll and follow-up study patients. We are also convening multi-partner videoconferences where subject matter experts and key opinion leaders discuss how to effectively activate and execute projects and programs within the landscape of the pandemic, and we have repurposed our headquarters support staff to manage these meetings.

In Equatorial Guinea (EG), where we’re partnering with Sanaria on their projects to develop a malaria vaccine, there were 16 confirmed cases of COVID-19 as of April 9, nine of which are on Bioko Island (population, ~350,000 people). As the staff at our clinical sites and labs in EG are deployed to aid with the COVID-19 response, we are concerned for our team members and all Equatoguineans, who are already struggling to control malaria, dengue and other infections. The malaria vaccine studies in EG are part of the larger Bioko Island Malaria Control Project (BIMCP), which is also exploring the effect of human movement patterns to and from the island on disease transmission. Because of this, we recognize how potentially devasting COVID-19 could be for this island population.

While there is no specific timeframe for when we can return to normal operations in our ongoing research to test much-needed vaccines and treatments for the many endemic diseases worldwide, we are dedicated to the health and wellbeing of our many employees, contractors and partners around the globe.

The team at FHI Clinical has spent years creating and sustaining worldwide research capacity. In partnership with our parent company, FHI 360, we have established lasting relationships with governments, regulatory agencies, other CROs, sponsors, academic institutions, sites and local communities. Together, we help ensure that countries are prepared to respond to threats to their people’s health. Because of our capacity, relationships and toolkit of resources, we are able to deploy as soon as a new virus like COVID-19 emerges. 

Contact us to discuss new or ongoing projects, including our recently announced partnership with IDRI for a COVID-19 treatment.

blog archive

2020 WOCIP Annual Conference: Educating, Empowering and Elevating Women of Color in Pharma Worldwide

“Educate, Empower, Elevate!” was the theme for the most recent conference for Women of Color in Pharma (WOCIP), a nonprofit aiming to promote the development and advancement of women of color who are employed in the pharmaceutical industry. We asked FHI Clinical team members, Tafoya Hubbard and LaTonya Jones to share some thoughts about their experiences during the 2020 two-day virtual event.

Read More »

Working Together to Expand Clinical Trials in Africa

We were honored to be part of the important discussion in a recent webinar from the African Academy of Sciences — “Strengthening the African clinical trials regulatory and ethics environment” — about extending research to areas where FHI 360/FHI Clinical has worked for decades. Participants included representatives of the AAS, Bill & Melinda Gates Foundation, World Health Organization (WHO) Regional Office for Africa, Novartis and FHI Clinical.

Read More »

Share this post

Share on linkedin
Share on twitter
Share on facebook